Comparative Pharmacology
Head-to-head clinical analysis: CARNEXIV versus TAMBOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARNEXIV versus TAMBOCOR.
CARNEXIV vs TAMBOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min)
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (CrCl < 35 mL/min).
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent